PRP for Glenohumeral Osteoarthritis
ConditionShoulder Osteoarthritis
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-100
SponsorHospital for Special Surgery, New York
About this trial
The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (\~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.
Eligibility criteria
Qualifiers
18-100 years old
Average NRS pain greater than or equal to 5/10 as a direct result of glenohumeral osteoarthritis (any severity: mild, moderate, or severe) and/or chondral lesion or loss
At least 3 months of pain after onset of symptoms that has failed conservative treatments, including physical therapy
MRI of the affected joint
Disqualifiers
Inability to hold non-steroidal anti-inflammatory drugs for 2 weeks prior and 1 month after the injection
Prior platelet-rich plasma injection
Steroid injection within 3 months of the initial injection
Hyaluronic acid within 6 months of the initial injection
Trial design
Treatments tested in this trial
- Low-dose PRP
- High-dose PRP
- Saline
Treatment groups
135 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov